Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission

European Journal of Clinical Pharmacology

Volumn 54, Issue 7, 1998, Pages 555-560

  Faure, C ^a   Andre J ^a   Pelatan, C ^a   Munck, A ^a   Giraud, M ^a   Cezard J P ^a   Jacqz Aigrain, E ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Inflammatory bowel disease; Prednisolone

Indexed keywords

METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISOLONE 3 SULFOBENZOATE; PREDNISONE;

ACUTE PHASE RESPONSE; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENTERITIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTOCOLITIS; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ACUTE-PHASE REACTION; ADMINISTRATION, ORAL; ADOLESCENT; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INJECTIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; PREDNISONE; REMISSION, SPONTANEOUS; TREATMENT OUTCOME;

EID: 0031765365     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050512     Document Type: Article

References (24)

1. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW (1979) National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 77: 847-869
2. Hyams JS, Ferry GD, Mandel FS, Gryhoski JD, Kilbort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT, Michener WM, Levy JS, Lesser ML (1991) Development and validation of a paediatric Crohn's disease activity index. J Pediatr Gastroenterol Nut 12: 439-447
3. Edwards FC, Truelove SC (1963) The course and prognosis of ulcerative colitis. Gut 4: 299-315
4. Smith RC, Rhodes J, Heatley RV, Hugues LE, Crosby DL, Rees BL, Jones H, Evans KT, Lawrie BW (1978) Low-dose steroids and clinical relapse in Crohn's disease: a controlled trial. Gut 19: 606-610
5. Derendorf H, Möllmann H, Rohdewald P, Rehder J, Schmidt EW (1985) Kinetics of methylprednisolone and its hemisuccinate ester. Clin Pharmacol Ther 37: 502-507
6. Szfler SJ, Ebling WF, Georgitis JW, Jusco WJ (1986) Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. Eur J Clin Pharmacol 30: 323-329
7. Al-Habet SMH, Rogers HJ (1989) Methylprednisolone pharmacokinetics after intravenous and oral administration. Br J Clin Pharmacol 27: 285-290
8. Assael BM, Banfi G, Appiani AC, Edefonti A, Jusko WJ (1982) Disposition of pulse dose methylprednisolone in adult and paediatric patients with nephrotic syndrome. Eur J Clin Pharmacol 23: 429-433
9. Bartoszek M, Brenner AM, Szefler SJ (1987) Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther 42: 424-432
10. Ito S, Kusunoki Y, Oka T, Ito Y, Okuno A, Yoshioka H (1992) Pharmacokinetics of high-dose methylprednisolone in children. Dev Pharmacol Ther 19: 99-105
11. Garg V, Jusko WJ (1994) Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm Drug Dispos 15: 163-172
12. Gambertoglio JG, Amend WJC, Benet LZ (1980) Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J Pharmacokinet Biopharm 8: 1-52
13. Etienne SD, Vandermeersch V, Chosidow O, Vu-Thi-My-Le C, Godeau P, Diquet B, Herson S (1990) Paramétres pharmacocinétiques de la prednisone et de la prednisolone chez le volontaire sain. Ann Med Interne 141: 507-511
14. Ferry JJ, Wagner JG (1987) The nonlinear pharmacokinetics of prednisone and prednisolone. II. Plasma protein binding of prednisone and prednisolone in rabbit and human. Biopharm Drug Disapos 8: 261-272
15. Rose JQ, Yurchak AM, Jusko WJ (1981) Dose dependent pharmacokinetics of prednisone and prednisolone in man. J pharmacokinet Biopharm 9: 389-417
16. Pickup ME (1979) Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 4: 111-128
17. Frev BM, Frey FJ (1990) Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 19: 126-146
18. Shaller JA, Williams SE, Turnberg LA, Houston JB, Rowland M (1983) Absorption of prednisolone in patients with Crohn's disease. Gut 24: 182-186
19. Bergrem H, Opedal I (1983) Bioavailability of prednisolone in patients with intestinal malabsorption: the importance of measuring serum binding protein. Stand J Gastroenterol 18: 545-549
20. Ellicot PR, Powell-Tuck J, Gillepspie PE, Laidlow JM, Lennard-Jones JE, English J, Chakraborty J, Marks V (1980) Prednisolone absorption in acute colitis. Gut 21: 49-51
21. Milsap RL, George DE, Szefler SJ, Murray KA, Lebenthal E, Jusko WJ (1983) Eflect of inflammatory bowel disease on absorption and disposition of prednisolone. Dig Dis Sci 28: 161-168
22. Olivesi A (1985) Normal absorption of oral prednisolone in children with active inflammatory bowel disease, including cases with proximal to distal small bowel involvement. Gastroenterol Clin Biol 9: 564-571
23. Green OC, Winter RJ, Kawahara FS, Phillips LS, Lewy PR, Hart RL, Pachman LM (1978) Pharmacokinetic studies of prednisolone in children. J Pediatr 93: 299-303
24. Hill MR, Sezfler SJ, Ball BD, Bartoszek M, Brenner AM (1990) Monitoring glucocortieoid therapy: a pharmacokinetic approach. Clin Pharmacol Ther 48: 390-398